A carregar...
Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, mos...
Na minha lista:
| Publicado no: | World J Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elmer Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5649879/ https://ncbi.nlm.nih.gov/pubmed/29147383 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/wjon779w |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|